82 results about "Rifamycin" patented technology

A method is provided for the treatment of age-related macular degeneration by administering various antibiotics, such as tetracycline and its derivatives, rifamycin and its derivatives, macrolides, and metronidazole, to a patient in a therapeutically effective amount.

The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.

The present invention features rifamycin analogs and methods of using these compounds to treat a variety of microbial infections.

The present invention relates to a method of controlling the two-component regulatory system of bacteria, in particular to an amrE gene and/or an amkE gene or homologous genes of the amrE gene or the amkE gene, which improves the yield of antibiotics and other useful secondary metabolites.

The invention features a method of delivering a drug to a diseased cell by linking the drug to a rifamycin derivative, compositions that include drug-rifamycin conjugates of the invention, and methods for treating disease using those compositions.

The invention discloses a preparation method for rifampin by using a micro-reaction apparatus. The method comprises the following steps (1) dissolving rifamycin oxazine in an organic solvent so as to obtain a homogeneous solution; (2) dissolving 1-methyl-4-nitropiperazine in an organic solvent so as to obtain a homogeneous solution; (3) respectively pumping the two homogeneous solutions obtained in the step (1) and the step (2) into the micro-reaction apparatus; and (4) collecting outflowing liquid which is a crude rifampin product. A micro-reactor has the characteristics of a great specific surface area, a high transmission rate, short contact time, a few by-products, strong heat transfer and mass transfer capability, rapid and direct amplification, high security, good operationality and the like. A micro-reaction system is a parallel system of a modular structure and has the characteristic of good portability; the system can be dispersively constructed in a place where a product is used and realizes on-site production and product supply, so portability of a chemical plant is realized indeed; moreover, production can be adjusted by increasing or decreasing channel numbers and replacing modules according to market conditions, so the system has high operational flexibility.

The invention discloses application of a rifamycin-nitroimidazole coupling molecule represented in a formula I in inhibition of anaerobic or facultative anaerobic ammonia producing floras in gastrointestinal tracts. The rifamycin-nitroimidazole coupling molecule represented in the formula I is similar to an antibacterial spectrum of rifaximin and has relatively strong antibacterial activity to common ammonia producing floras in the gastrointestinal tracts; and meanwhile, the rifamycin-quinolizidone dual-target molecule has the property of low spontaneous drug resistance frequency and has very good application prospects in prevention and treatment of infection of hepatic encephalopathy and relevant anaerobic bacteria. The formula is as shown in the specification.

The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.

The present invention provides an anti-tuberculosis gel preparation, which belongs to the technical field of ultrasonic therapy. The anti-tuberculosis gel preparation comprises, on the basis of dosage percentage, 0.5 to 8% of hydrophilic polymer materials, 0.5 to 15% of penetration enhancers, 2 to 10% of humectants, 0.5 to 3% of isoniazid, 2 to 5% of rifamycin and water. The preparation method for the gel preparation comprises the following steps: 1, preparing the components of gel preparation in proportion; 2, immersing the hydrophilic polymer materials in water to dissolve the materials; 3, adding the penetration enhancers and humectants into the obtained solution and carrying out stirring until the penetration enhancers and humectants dissolve; 4, adding isoniazid and rifamycin into the solution and carrying out uniform mixing under stirring. When used for ultrasonic medicine phoresis therapy, the gel preparation can guarantee that carried drug components smoothly penetrate into bodies to exert pharmacological effects and treat tuberculosis, besides exerting an effect of ultrasonic coupling.

The invention provides anti-Staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.

The compounds of formula (1), their pharmaceutically acceptable salts and their solvates, wherein R¹ is a radical selected between hydrogen and alkyl; R² is selected from hydroxyalkyl, phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; R³ is selected from phenyl, phenyl mono-substituted and phenyl di-substituted in positions 3 and 4; the substituents of the phenyl of R² and R³ selected from halogen, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxyl and R⁴ is selected from hydrogen, alkyl allyl and homoallyl, they are useful for the treatment of mycobacterial infections, in particular for the treatment of infections produced by Mycobacterium tuberculosis, Mycobacterium avium-intracellulare complex or Mycobacterium kansasii.

The disclosure relates to rifamycin analog compounds, intermediates and precursors thereof, and pharmaceutical compositions capable of inhibiting bacterial growth (e.g., S. aureus growth) and treating bacterial infections (e.g., S. aureus infections). The disclosure further relates to antibody-drug conjugates of rifamycin analog compounds and antibodies, for example, antibodies specific for infectious disease-related targets such as membrane glycoprotein receptor (MSR1), wall teichoic acids (WTA) or Protein A, and methods of use thereof to inhibit bacterial growth and treat bacterial infections.

The invention relates to an externally applied preparation for treating whelks. The externally applied preparation is prepared by dissolving one or several medicaments of erythrocin, aureomycin, chloramphenicol, lincomycin hydrochloride, tobramycin, natamycin, norfloxacin, rifampicin, cyclosporine, gentamicin and neomycin into a polysaccharide aqueous solution. An obtained solution contains 0.005-1 wt% of medicaments and 0.01-30 wt% of glucan, xyloglucan, mycose, sea-tangle polysaccharides, tamarind gum, pectin or other Chinese medicinal herb polysaccharides, or a proper quantity of glucose, sodium chloride and potassium chloride are added to the aqueous solution to prepare a plaster preparation. The externally applied preparation has quick effect and definite curative effect on the whelks or acne and has small stimulation to the skin, extremely light skin decrustation degree and no obvious toxic or side effects. The process of the preparation can guarantee the chemical stability of each component in a production process.

Rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms are claimed in this invention. The inventive rifamycin derivatives are uniquely designed in that they have a rifamycin moiety covalently linked to a linker group through the C-3 carbon of the rifamycin moiety and the linker is, in turn covalently linked to a therapeutic moiety or antibacterial agent/pharmacophore. The therapeutic moiety can be a quinolone, an oxazolidinone, a macrolide, an aminoglycoside, a tetracycline core or a structure/pharmacophore associated with an antibacterial agent.

The invention relates to an external preparation for treating seborrheic dermatitis, comprising at least one effective parasite-expelling medicament which is extracted from etreptomyces and used as an active component, i.e. large ring lactone, such as abamectin, or chemical modified or synthetic derivative ivermectin, one or more of bactericidal antibiotics in erythrocin, aureomycin, chloromycetin, lincomycin hydrochloride, tobramycin, natamycin, norfloxacin, rifampicin, cyclosporine, gentamicin and neomycin and at least another traditional Chinese medical herbal amylase which are contained in carriers for the surface administration and the cutaneous penetration of the active component, or suitable amounts of glucose, sodium chloride or potassium chloride can be also added to the external preparation. The invention has rapid constringency and demanded efficacy for the seborrheic dermatitis, little excitation irritation to the skin, extremely mild skin peeling without obvious toxic and side effects; and the preparation process can ensure the chemical stabilities of various contents in the production process. The invention can be also used for treating whelks.